Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Guangdong Fapon Biotech Co., Ltd.

Download Mobile App




Blood Test Could Provide Earlier Diagnosis of Liver Disease

By LabMedica International staff writers
Posted on 06 Sep 2012
A new "traffic light" test could be used in primary care to diagnose liver fibrosis and cirrhosis in high-risk populations.

Called the Southampton Traffic Light (STL) test, it combines several different tests and clinical markers, which are given a score that indicates the patient's likelihood of developing liver fibrosis and liver cirrhosis.

The STL algorithm combines two serum markers of fibrosis, collagen p3 n peptide (P3NP) and hyaluronic acid (HA), together with platelet count, and can be calculated in two ways: either with a complex exponential function derived from logistic regression analysis, or, alternatively, with a simple clinical rule for the individual test results:
HA >30 μg/L or P3NP >5.5 μg/L–score +1
HA >75 μg/L–score +2
Platelet count <150 × 109/L–score +1
Total score: 0 = green, 1 = amber, 2 or more = red

The “traffic light” aspect refers to grouping of the results of a combination of blood tests into “high risk,” “intermediate risk,” and “low risk” categories in terms of the patients' risk of developing serious liver disease. More...
The results are therefore actually numbers rather than traffic light-colored test tubes etc. The novel part is the grouping together of the individual tests such that their combined predictive value for the presence of liver disease is much greater than the tests when used individually.

The result is interpreted as follows: red means that the patient has liver scarring (fibrosis) and may even have cirrhosis, green means that there is no cirrhosis and the patient is highly unlikely to die from liver disease over the next five years. Amber means there is at least a 50:50 chance of scarring with a significant possibility of death within five years, and patients are advised to stop drinking to avoid further disease and death.

The test was given to more than 1,000 patients and their progress was followed and monitored, in some cases for several years, to assess the accuracy of the test in predicting whether they developed liver fibrosis or cirrhosis. It was accurate in severe liver disease but is not meant to be a substitute for clinical judgment or other liver function tests. However, it can provide family doctors with a means to assess the potential severity of liver fibrosis in high-risk patients such as heavy drinkers, those with type II diabetes, or obese individuals.

Devised by Dr. Nick Sheron and colleagues at University of Southampton (Southampton, United Kingdom) and Southampton General Hospital (Southampton, United Kingdom), details of the test appear in the September 2012 issue of the British Journal of General Practice (BJGP).

Prof. Sir Ian Gilmore, chair of the Alcohol Health Alliance commented, "One of the challenges of liver disease, which is rising dramatically in this country, is the silent nature of the condition until it is often too late to reverse the damage. However, minor changes in standard liver blood tests are so common that it is difficult for GPs to know when to refer for specialist advice. This large study from Dr .Sheron and colleagues in Southampton may prove really useful for guiding the right patients towards specialist care in a timely way."

Related Links:
University of Southampton
Southampton General Hospital




Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
New
Silver Member
Vitamin D Assay
EZ Vitamin D Assay
Gold Member
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Measuring six variants from one sample may improve research efficiency and support clinical trials of amyloid biology in Alzheimer’s disease and related conditions (Image Credit: Adobe Stock)

Plasma Assay Measures Six Amyloid Beta Peptides for Alzheimer’s Treatment Research

Alzheimer’s disease research and related neurological studies often require tools that can characterize brain amyloid pathology and amyloid beta biology. Blood-based biomarker assays may help researchers... Read more

Molecular Diagnostics

view channel
Image: A new study links broad genomic sequencing before first-line therapy to longer survival, supporting its role in treatment decisions (Image Credit: Shutterstock)

Study Supports Broad Genomic Profiling Before First-Line Lung Cancer Treatment

Biomarker testing plays a critical role in advanced non-small cell lung cancer by identifying patients who may benefit from targeted therapies. However, testing only one or two genes can miss actionable... Read more

Immunology

view channel
Image: The findings underscore the importance of aligning allergy testing with clinical history and diagnostic guidelines to reduce inappropriate testing and its consequences (Image Credit: iStock)

Survey Finds Gap Between Food Allergy Testing Awareness and Clinical Practice

Food allergy evaluation can be challenging when laboratory results do not match clinical symptoms. Broad food allergy panels may detect sensitization without confirming an actual allergy, potentially leading... Read more

Industry

view channel
Image Credit: iStock

C2N Makes PrecivityAD2 Alzheimer’s Blood Test Available to Clinicians

Diagnosing Alzheimer’s disease can be challenging, particularly in patients with mild cognitive impairment or early dementia. Assessing brain amyloid pathology can guide clinical decisions, but diagnostic... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.